Product Specifications for Recombinant Human PILR-alpha Fc Chimera Protein, CF
Chinese Hamster Ovary cell line, CHO-derived human PILR-alpha protein
Human PILR-alpha (Thr25-Thr196) Accession # Q9UKJ1.3
Human IgG1 (Pro100-Lys330)
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis
Predicted Molecular Mass
57-64 kDa, under reducing conditions
Measured by its binding ability in a functional ELISA. When Recombinant Human PANP Fc Chimera (Catalog # 7920-PN) is coated at 5.00 µg/mL (100 μL/well), Recombinant Human PILR- alpha Fc Chimera binds with an ED50 of 0.150- 0.900 μg/mL.
Scientific Data Examples for Recombinant Human PILR-alpha Fc Chimera Protein, CF
Recombinant Human PILR-alpha Fc Chimera Protein SDS-PAGE.
2 μg/lane of Recombinant Human PILR-alpha Fc Chimera (Catalog # 10802-PR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 57-64 kDa and 114-128 kDa, respectively.
Formulation, Preparation and Storage
What does CF mean?
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our
Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant
protein to be stored at a more dilute concentration.
The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or
as an ELISA standard.
In contrast, the carrier free protein is recommended for applications, in which the presence of BSA
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitute at 500 μg/mL in PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Paired immunoglobulin-like type 2 receptor-alpha (PILRA) is one of two members that belong to a small family of immunoregulatory Ig-superfamily receptors (1-4). It is a counterpart to PILRB and the PILRs represent one of many pairs of Ig-like domain-containing receptors that participate in immune regulation (1, 2). Mature human PILRA consists of an extracellular domain (ECD) with one V-type Ig-like domain, a transmembrane domain, and a cytoplasmic domain with two immunoreceptor Tyr‑based inhibitory (ITIM) motifs. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs makes PILRA an inhibitory receptor (1-4). The ECD of human PILRA shares 42% and 40% amino acid sequence identity with mouse and rat PILRA, respectively. Three potential isoforms for human PILRA have been reported. PILRA is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV1 (in human) (7), PANP (PILR-associated neural protein) (8) and NPDC1 plus collectin-12 (10). Although PILRA and PILRB are highly similar in their ECD amino acid sequence, they do not necessarily share the same ligands, as PILRB fails to bind to gB and PANP (8, 10). PILRA binding appears to be dependent upon the presence of a poorly-defined peptide sequence coupled to a sialylated, O-linked carbohydrate motif but its exact function remains unclear (5, 9-12). Up-regulation of PILRA in the early stage of immune reaction and its subsequent binding to CD99 may lead to a down-regulation of the inflammatory response (10). Genome-wide association studies (GWAS) have linked PILRA to Alzheimer's Disease (AD) through association of PILRB with ZCWPW1 (13,14). It was further supported that ZCWPW1 locus SNP rs1476679 was associated with reduced PILRA levels suggesting a potential role for the gene in AD (15). The missense variant (G78R, rs1859788) of PILRA is thought to be the causal allele for the confirmed AD risk locus. The variant reduced the binding of PILRA to several ligands including a novel ligand, complement component 4A, and herpes simplex virus 1 (HSV-1) glycoprotein B (16). The observed protection from AD risk by PILRA G78R variant provided a new candidate for the therapeutic target.
Wilson, M.D. et al. (2006) Physiol. Genomics 27:201.
Lanier, L.L. (2001) Curr. Opin. Immunol. 13:326.
Fournier, N. et al. (2000) J. Immunol. 165:1197.
Shiratori, I. et al. (2004) J. Exp. Med. 199:525.
Mousseau, D.D. et al. (2000) J. Biol. Chem. 275:4467.
SwissProt Accession # Q9UKJ1.
Tato, C.M. et al. (2012) PLoS ONE 7:e31680.
Satoh, T. et al. (2008) Cell 132:935.
Tabata, S. et al. (2008),J. Biol. Chem. 283:8893.
Sun, Y. et al. (2012) J. Biol. Chem. 287:15837.
Wang, J. et al. (2008) J. Biol. Chem. 180:1686.
Arii, J. et al. (2010) J. Virol. 84:10733.
Karch, CM. et al. (2016) PLoS ONE. 11:1-22.
Allen, M. et al. (2015) Neurol Genet. 1:e15 (PubMed: 27066552).
Patel, T. et al. (2018) Neurolpathol Appl Neurobiol. 44(5):506.
Rathore, N. et al. (2018) PLoS Genet. 14(11):e1007427.
Which Brands are Currently Available on bio‑techne.com? R&D Systems, Tocris Bioscience and ProteinSimple branded products are available to purchase through bio‑techne.com. ProteinSimple branded instruments are available to quote. ACD branded products will be available on bio‑techne.com in the near future. Novus Biologicals branded products are not currently available on bio‑techne.com and can be found at novusbio.com.
Setting the standard in quality research reagents for over 30 years
A trusted leader in quality life science reagents
Your trusted supplier for innovative and high performance life science reagents
Proprietary systems and consumables for simpler, more quantitative and affordable protein analysis
Proprietary RNAscope® technology capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity
A world leader in developing liquid biopsy based diagnostics